CD274 and neoplasm: Additionally, in the FDA pooled analysis of 1430 patients (39% KRASm) from registrational clinical trials discussed above, 67% of patients were current or former smokers in the overall cohort, and 60% had a positive PDL-1 score, and no difference in outcomes was demonstrated between patients with KRASm and KRASwt tumours [27].